Innoviva, Inc.

INVA · Nasdaq · SIC 2834: Pharmaceutical Preparations
351
SEC Filings

Business Summary

PART I Overview Innoviva, Inc. (Innoviva, the Company, the Registrant or we and other similar pronouns) is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic healthcare assets. Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR /BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and A...

Next Earnings

Q2 FY2026 — expected 2026-08-13

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionINVAdiscussed_in_filing Cybersecurity
topic_mentionINVAdiscussed_in_filing Cybersecurity
topic_mentionINVAdiscussed_in_filing Healthcare & Bio
topic_mentionINVAdiscussed_in_filing Platform & Ecosystem
topic_mentionINVAdiscussed_in_filing Healthcare & Bio
topic_mentionINVAdiscussed_in_filing Platform & Ecosystem

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-252025-12-310001193125-26-071776EDGAR98K words
2025-02-262024-12-310000950170-25-027864EDGAR—
2024-02-292023-12-310000950170-24-023237EDGAR—
2023-02-282022-12-310000950170-23-005168EDGAR—
2022-02-282021-12-310000950170-22-002169EDGAR—
2021-02-252020-12-310001104659-21-028328EDGAR—
2020-02-192019-12-310001104659-20-022807EDGAR—
2019-02-192018-12-310001047469-19-000541EDGAR—
2018-02-232017-12-310001047469-18-001016EDGAR—
2017-02-282016-12-310001047469-17-001057EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-052025-09-300001193125-25-267040EDGAR34K words
2025-08-062025-06-300000950170-25-104126EDGAR—
2025-05-072025-03-310000950170-25-065765EDGAR—
2024-11-062024-09-300000950170-24-122375EDGAR—
2024-07-312024-06-300000950170-24-088661EDGAR—
2024-05-082024-03-310000950170-24-055832EDGAR—
2023-11-012023-09-300000950170-23-057530EDGAR—
2023-08-022023-06-300000950170-23-037296EDGAR—
2023-05-092023-03-310000950170-23-019835EDGAR—
2022-11-092022-09-300000950170-22-023933EDGAR—
2022-07-272022-06-300000950170-22-013224EDGAR—
2022-05-052022-03-310000950170-22-007798EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-02-250001193125-26-071974EDGAR4K words
2025-11-050001104659-25-107014EDGAR—
2025-08-060001104659-25-074730EDGAR—
2025-05-210001104659-25-051614EDGAR—
2025-05-070001104659-25-045556EDGAR—
2025-02-260001104659-25-017461EDGAR—
2024-11-060001104659-24-114800EDGAR—
2024-07-310001104659-24-084357EDGAR—
2024-06-200001104659-24-073416EDGAR—
2024-05-130001104659-24-060280EDGAR—

351 total filings indexed. 319 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001080014
TickerINVA
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: ffe0abf6bf608cc8ee86cd789008b7b945d07a9409f66b75ab7956d355e91631
parent: 198827536895796c57aa07644ef8d94feda21f64ad9c74eff6fc01f93023f031
content hash: 33ba9b40ee8fa992c4b167b371d0b1d300013be3dc4acbbad45044f99325b890
signed: 2026-04-13T04:45:43.270Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf